Given the complexity of the gut microbiome and growing scrutiny of GLP-1 medications, Akkermansia offers a promising natural alternative
According to the applicant, no existing device categories for pass-through payment appropriately describe the Axoguard HA+ Nerve Protector TM because the existing device categories C1763 (Connective tissue, non-human (includes synthetic)), C1765 (Adhesion barrier), and C1781 (Mesh (implantable)) describe similar, but distinct products
Designed for individuals who may not be candidates for traditional surgery or who wish to optimize their health before or after a procedure, LeanLife provides the medical expertise and accountability essential to achieving long-term results
Compliance with Ethics Guidelines As this study involved retrospectively collected de-identified data, which was analyzed without further interaction with the human subjects, it was deemed to be exempt from institutional review board review
Takeda Pharmaceutical is developing the Nimbus-discovered tyrosine kinase 2 (TYK2) inhibitor zasocitinib as a once-daily oral treatment for moderate-to-severe plaque psoriasis
